Protective effects of hesperetin on lipopolysaccharide-induced acute lung injury by targeting MD2

doi:10.1016/j.ejphar.2019.02.042

科研成果详情

题名	Protective effects of hesperetin on lipopolysaccharide-induced acute lung injury by targeting MD2
作者	Ye, Jinyan1,2; Guan, Minqiang3; Lu, Yao1; Zhang, Dan1; Li, Chengye1; Li, Yuping1; Zhou, Caicun 4
发表日期	2019-06-05
发表期刊	EUROPEAN JOURNAL OF PHARMACOLOGY 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Acute lung injury Inflammation Myeloid differentiation 2 Hesperetin
其他关键词	INFLAMMATORY RESPONSES
摘要	Inflammation plays an important role in acute lung injury (ALI). Hesperetin (HES), a natural flavanone and an aglycone of hesperidin, has established potent anti-inflammatory activity. The aim of this study was to evaluate the potential protective effect of HES on lipopolysaccharide (LPS)-induced ALI in mice and to illuminate its possible directly target. Results indicated that HES pretreatment significantly attenuated LPS-induced pulmonary pathological injury, total protein concentration, markedly decreased the number of neutrophils and the levels of inflammatory cytokines, TNF-alpha and IL-6, in ALI model in vivo and in vitro. Meanwhile, pretreatment with HES dramatically reduced myeloperoxidase (MPO) activity in LPS-induced ALI mice. Additionally, using molecular docking and co-immunoprecipitation assay, HES showed a directly bind with myeloid differentiation 2 (MD2), in which HES could inhibit MAPK activation, regulate I kappa B degradation, block the interaction MD2 and its coreceptor Toll-like receptor 4 (TLR4). Taken together, HES showed a significantly protective effect against LPS-induced ALI, which might be associated with MD2 protein. These results attested HES worthy of further progress into an adjunctive potential drug for the treatment for ALI.
资助项目	Wenzhou Municipal Science and Technology Bureau, Zhejiang province, China [Y20120080]
出版者	ELSEVIER SCIENCE BV
出版地	AMSTERDAM
ISSN	0014-2999
EISSN	1879-0712
卷号	852 页码:151-158
DOI	10.1016/j.ejphar.2019.02.042
页数	8
WOS类目	Pharmacology & Pharmacy
WOS研究方向	Pharmacology & Pharmacy
WOS记录号	WOS:000464982100016
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	30807747
SCOPUSEID	2-s2.0-85062863396
通讯作者地址	[Ye, Jinyan]Department of Respiratory and Critical Care Medicine,First Affiliated Hospital of Wenzhou Medical University,Shangcai Village, Nanbaixiang Town,Ouhai District,325000,China
Scopus学科分类	Pharmacology
引用统计	被引频次：22[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/6301
专题	附属第一医院实验动物中心
通讯作者	Ye, Jinyan
作者单位	1.Department of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou,325000,China; 2.The Third Affiliated Hospital of Soochow University,Changzhou,213000,China; 3.Laboratory Animal Center,Wenzhou Medical University,Wenzhou,325000,China; 4.Department of Oncology,Shanghai Pulmonary Hospital,Tongji University School of Medicine,Shanghai,200433,China
第一作者单位	附属第一医院
通讯作者单位	附属第一医院
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Ye, Jinyan,Guan, Minqiang,Lu, Yao,et al. Protective effects of hesperetin on lipopolysaccharide-induced acute lung injury by targeting MD2[J]. EUROPEAN JOURNAL OF PHARMACOLOGY,2019,852:151-158.
APA	Ye, Jinyan., Guan, Minqiang., Lu, Yao., Zhang, Dan., Li, Chengye., ... & Zhou, Caicun. (2019). Protective effects of hesperetin on lipopolysaccharide-induced acute lung injury by targeting MD2. EUROPEAN JOURNAL OF PHARMACOLOGY, 852, 151-158.
MLA	Ye, Jinyan,et al."Protective effects of hesperetin on lipopolysaccharide-induced acute lung injury by targeting MD2".EUROPEAN JOURNAL OF PHARMACOLOGY 852(2019):151-158.